NRIX Nurix Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Clinical stage biopharma focused on targeted protein degradation using AI-integrated DEL-AI platform for oncology, inflammation, and immunology treatments
• • Advanced lead BTK degrader bexobrutideg in Phase 2 pivotal trial with FDA Fast Track and EMA PRIME designations for relapsed/refractory CLL and WM
• • Resumed Phase 1 study of dual BTK/Ikaros/Aiolos degrader zelebrudomide after FDA partial clinical hold lifted in 2024
• • $482M non-dilutive funding through collaborations with Gilead, Sanofi, Pfizer; potential $6.1B future milestones and royalties
• • Introduced oral CBL-B inhibitor NX-1607 in Phase 1 trials for solid tumors and gained UK Innovation Passport in 2022 for accelerated market access

Risk Factors

• • Regulatory risk: FDA partial clinical hold on zelebrudomide enrollment in 2023 due to manufacturing change, lifted in August 2024
• • Macroeconomic risk: Uncertainty from inflation, interest rates, tariffs, debt ceiling risks, and global conflict impacts clinical trials, supply chain, personnel
• • Operational risk: Dependency on third-party manufacturing for chirally controlled zelebrudomide form critical to ongoing Phase 1b dose escalation
• • Market disruption risk: Competitive threat from established BTK inhibitors and non-covalent BTK inhibitors used in relapsed/refractory CLL patients
• • Financial risk: Net losses of $264.5 million in FY 2025 with $592.9 million cash runway for only 12 months, needing substantial additional capital beyond that

Management Discussion & Analysis

• • No revenue figures or profitability metrics disclosed in provided text
• • No segment performance data available
• • No cash flow, buyback, dividend, or capex details included
• • Forward-looking statements mention risks and uncertainties without specific guidance or outlook

What are the latest NRIX SEC filings in 2026?

Nurix Therapeutics, Inc. (NRIX) has filed a 10-K annual report on January 28, 2026, a 10-Q quarterly report on April 8, 2026, an 8-K current report on July 9, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did NRIX file its most recent 10-K annual report?

Nurix Therapeutics, Inc. (NRIX) filed its most recent 10-K annual report on January 28, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view NRIX 10-Q quarterly reports?

Nurix Therapeutics, Inc. (NRIX)'s most recent 10-Q quarterly report was filed on April 8, 2026. SignalX displays every NRIX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has NRIX filed recently?

Nurix Therapeutics, Inc. (NRIX)'s most recent 8-K was filed on July 9, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find NRIX insider trading activity (Form 4)?

SignalX aggregates every NRIX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does NRIX file with the SEC?

Nurix Therapeutics, Inc. (NRIX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new NRIX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Nurix Therapeutics, Inc. (NRIX).

What is NRIX's SEC CIK number?

Nurix Therapeutics, Inc. (NRIX)'s SEC CIK (Central Index Key) number is 1549595. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1549595 to look up all NRIX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find NRIX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Nurix Therapeutics, Inc. (NRIX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.